Benchmark raises two new funds totaling $2 billion, shifts focus to mature startups

The legendary VC firm is launching its first-ever dedicated growth fund after riding Cerebras to roughly 12x returns.

Share

Add us on Google by Editorial Team Jun. 4, 2026

Benchmark, the Silicon Valley firm famous for small funds and big bets, just did something very un-Benchmark. It raised approximately $2 billion across two new funds, nearly doubling the size of what it historically deploys and adding a growth-stage vehicle for the first time in its history.

The fundraise breaks down into a $750 million traditional early-stage fund and a $1.25 billion growth fund targeting later-stage, more established startups. For a firm whose previous funds averaged around $425 million, this is not a tweak. It’s a philosophical pivot.

Why Benchmark is changing its playbook

Benchmark has built its reputation on a specific model for decades: small funds, equal partnerships, early-stage conviction bets. The firm backed eBay, Twitter, Uber, and a long list of companies that became household names.

Advertisement

Benchmark invested in Cerebras, the AI chipmaker, across multiple funding rounds. When Cerebras went public in May 2026, the firm reportedly achieved roughly 12x returns on that investment. The key detail: much of that value came from later-stage participation, not just the early seed check.

The growth fund represents Benchmark’s first-ever dedicated vehicle for late-stage investments. The plan is to make a limited number of high-concentration bets through this fund, rather than spraying capital across dozens of portfolio companies.

What this means for venture capital

Benchmark’s move is notable because the firm has historically been the loudest advocate for the small-fund model. When other venture firms were racing to raise multi-billion-dollar mega-funds in 2021 and 2022, Benchmark stayed disciplined. Partners split carry equally. Fund sizes stayed modest.

This dual-fund structure could also attract a different class of limited partners. Institutional investors, pension funds, endowments, and sovereign wealth funds often prefer the risk profile of growth-stage investing over the binary outcomes of early-stage venture. By offering both vehicles, Benchmark can appeal to LPs who want early-stage exposure alongside the more predictable cash flows of later-stage companies approaching liquidity events.

What this means for investors and founders

The Cerebras experience demonstrated that staying invested through an IPO can generate returns that rival or exceed early-stage multiples. The growth fund’s focus on high-concentration investments means Benchmark won’t be competing for every Series C and D deal, which could drive up valuations for the specific companies it chooses to back.

Growth-stage investing is a fundamentally different game than early-stage. Entry prices are higher, the margin for error is thinner, and the returns depend more on precise timing around liquidity events. The $1.25 billion growth fund also represents a concentration risk that Benchmark has historically avoided. If one or two of those high-conviction bets go sideways, the losses will be proportionally larger than anything the firm has experienced with its smaller early-stage funds.

Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.